Investors are poised to add Voyager Therapeutics Inc (VYGR) Stock to their long term portfolios

At the time of writing, Voyager Therapeutics Inc [VYGR] stock is trading at $3.47, up 9.12%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VYGR shares have gain 11.22% over the last week, with a monthly amount drifted -1.98%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Previously, Citigroup started tracking the stock with Buy rating on December 02, 2024, and set its price target to $12. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $15 on October 16, 2024. Guggenheim initiated its recommendation with a Buy and recommended $22 as its price target on March 26, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on March 19, 2024, and assigned it a price target of $30. In a note dated March 07, 2024, Citigroup initiated an Buy rating and provided a target price of $16 on this stock.

For the past year, the stock price of Voyager Therapeutics Inc fluctuated between $2.64 and $9.55. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Voyager Therapeutics Inc [NASDAQ: VYGR] shares were valued at $3.47 at the most recent close of the market. An investor can expect a potential return of 188.18% based on the average VYGR price forecast.

Analyzing the VYGR fundamentals

According to Voyager Therapeutics Inc [NASDAQ:VYGR], the company’s sales were 66.96M for trailing twelve months, which represents an -66.83% plunge. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -1.52%, Pretax Profit Margin comes in at -1.25%, and Net Profit Margin reading is -1.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.27 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.28 points at the first support level, and at 3.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.58, and for the 2nd resistance point, it is at 3.69.

Ratios To Look Out For

It is important to note that Voyager Therapeutics Inc [NASDAQ:VYGR] has a current ratio of 6.10. Also, the Quick Ratio is 6.10, while the Cash Ratio stands at 1.86. Considering the valuation of this stock, the price to sales ratio is 2.87, the price to book ratio is 0.70.

Transactions by insiders

Recent insider trading involved Ferguson Toby, Chief Medical Officer, that happened on Apr 02 ’25 when 10086.0 shares were sold. President and CEO, Sandrock Alfred completed a deal on Apr 02 ’25 to sell 10885.0 shares. Meanwhile, Officer Sandrock Alfred bought 10885.0 shares on Apr 02 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.